New anti–vascular endothelial growth factor (VEGF) therapies are improving retinal disease management by providing patients ...

Privately-held Ashvattha Therapeutics, a Californian firm advancing a new class of nanomedicine therapeutics that traverse ...

A study suggests that patients with wet AMD may regain vision through a novel approach — removing abnormal blood vessels and ...

Zervimesine is an investigational oral, once-daily pill being developed for the treatment of CNS diseases, including ...

Dry AMD causes diminished vision accompanied by loss of central retinal pigmented epithelium (RPE) cells in individuals aged 55 and older. There are no approved vision-improving treatments for dry ...

Needham initiated coverage on Ocular Therapeutix Inc (NASDAQ:OCUL), noting the company’s lead asset, Axpaxli, an ...

Right now, the IND-enabling studies are made to test the safety, tolerability, vector biodistribution, transgene expression, ...

Baseline angiographic lesion characteristics predictive of clinical response Published in peer-reviewed journal Ophthalmic Surgery, Lasers and Imaging Retina MELBOURNE, Australia and PRINCETON, N.J., ...

Age-related macular degeneration (AMD) AMD is a common eye condition that happens as you get older. It affects the macula, ...

Wet AMD in its early stages can be treated with drugs to reduce the formation of new blood vessels, but this treatment is inefficient in cases where blood vessel formation is already in its advanced ...

Read the Market Summary Here:- https://reportocean.com/industry-verticals/sample-request?report_id=bwcc18604 ...